Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | CASP1 | P29466 | 2/20 | 1.00 |
| ▸ | CASP7 | P55210 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CDC42 | P60953 | 1/20 | 0.46 |
| ▸ | RAC1 | P63000 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL4022544 | 0.98 | KDM4E (1.00) | KDM4ECYP3A4MAPTALDH1A1HPGD | |
| SCHEMBL278878 | 0.98 | KDM4E (0.97) | KDM4ECYP3A4MAPTALDH1A1HPGD | |
| SCHEMBL12942447 | 0.90 | KDM4E (0.82) | KDM4ECYP3A4MAPTALDH1A1HPGD | |
| SCHEMBL12903638 | 0.87 | KDM4E (0.76) | KDM4ECYP3A4MAPTALDH1A1HPGD | |
| SCHEMBL17539940 | 0.87 | ALDH1A1 (0.76) | KDM4ECYP3A4MAPTALDH1A1HPGD | |
| SCHEMBL29331926 | 0.87 | ALDH1A1 (0.76) | KDM4ECYP3A4MAPTALDH1A1HPGD | |
| SCHEMBL13076896 | 0.86 | CYP3A4 (0.74) | KDM4ECYP3A4MAPTALDH1A1HPGD | |
| SCHEMBL179694 | 0.86 | CYP3A4 (0.74) | KDM4ECYP3A4MAPTALDH1A1HPGD | |
| SCHEMBL191878 | 0.86 | KDM4E (0.74) | KDM4ECYP3A4MAPTALDH1A1HPGD | |
| SCHEMBL13076467 | 0.86 | KDM4E (0.74) | KDM4ECYP3A4MAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | claimed |
| EP-2014651-A1 | Compounds and methods for modulating Rho GTPases | Exonhit Therapeutics SA (FR) | 2009-01-14 | — | — | EP | claimed |
| US-20230024933-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4055164-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin (DE) | 2022-09-14 | — | — | EP | disclosed |
| US-11331333-B2 | Treatment of aberrant fibroblast proliferation | Georg-August-Universität Göttingen Stiftung Öffentichen Rechts, Universitätsmadizin (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20210137963-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2021-05-13 | — | — | US | disclosed |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | disclosed |
| EP-2014651-A1 | Compounds and methods for modulating Rho GTPases | Exonhit Therapeutics SA (FR) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024933-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | EYA2, EYA3, PTP4A1 | KDM4E 1039/4885CYP3A4 4733/4885MAPT 3012/4885 |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | RAC1, RAC2, RAC3 | KDM4E 3958/4885CYP3A4 4571/4885MAPT 2679/4885 |
| US-20210137963-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | EYA2, EYA3, PTP4A1 | KDM4E 1039/4885CYP3A4 4733/4885MAPT 3012/4885 |
| US-11331333-B2 | Treatment of aberrant fibroblast proliferation | EYA2, EYA3, PTP4A1 | KDM4E 1039/4885CYP3A4 4733/4885MAPT 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.